A few good reasons to use nanobodies for cancer treatment.
Brain tumor
Cancer
Cancer therapy
Half-life extension
Nanobodies
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
29
04
2023
received:
15
01
2023
accepted:
17
05
2023
medline:
11
9
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
mAbs have been instrumental for targeted cancer therapies. However, their relatively large size and physicochemical properties result in a heterogenous distribution in the tumor microenvironment, usually restricted to the first cell layers surrounding blood vessels, and a limited ability to penetrate the brain. Nanobodies are tenfold smaller, resulting in a deeper tumor penetration and the ability to reach cells in poorly perfused tumor areas. Nanobodies are rapidly cleared from the circulation, which generates a fast target-to-background contrast that is ideally suited for molecular imaging purposes but may be less optimal for therapy. To circumvent this problem, nanobodies have been formatted to noncovalently bind albumin, increasing their serum half-life without majorly increasing their size. Finally, nanobodies have shown superior qualities to infiltrate brain tumors as compared to mAbs. In this review, we discuss why these features make nanobodies prime candidates for targeted therapy of cancer.
Identifiants
pubmed: 37366246
doi: 10.1002/eji.202250024
doi:
Substances chimiques
Single-Domain Antibodies
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2250024Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Beck, A., Goetsch, L., Dumontet, C. and Corvaïa, N., Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 2017. 16: 315-337.
Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y., Antibody-drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 2022. 7: 93.
Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S. and Thorne, R. G., Passive immunotherapies for central nervous system disorders: current delivery challenges and new approaches. Bioconjug. Chem. 2018; 29: 3937-3966.
Schoonooghe, S., Laoui, D., Van Ginderachter, J. A., Devoogdt, N., Lahoutte, T., De Baetselier, P. and Raes, G., Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology 2012; 217: 1266-1272.
Stijlemans, B., Conrath, K., Cortez-Retamozo, V., Van Xong, H., Wyns, L., Senter, P., Revets, H. et al., Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem. 2004; 279: 1256-1261.
Kunz, P., Zinner, K., Mücke, N., Bartoschik, T., Muyldermans, S. and Hoheisel, J. D., The structural basis of nanobody unfolding reversibility and thermoresistance. Sci. Rep. 2018; 8: 7934.
Ackaert, C., Smiejkowska, N., Xavier, C., Sterckx, Y. G. J., Denies, S., Stijlemans, B., Elkrim, Y. et al., Immunogenicity risk profile of nanobodies. Front. Immunol. 2021. 12: 632687.
Vaneycken, I., D'huyvetter, M., Hernot, S., De Vos, J., Xavier, C., Devoogdt, N., Caveliers, V. et al., Immuno-imaging using nanobodies. Curr. Opin. Biotechnol. 2011. 22: 877-881.
de Marco, A., Recombinant expression of nanobodies and nanobody-derived immunoreagents. Protein Expr. Purif. 2020. 172: 105645.
Yang, E., Liu, Q., Huang, G., Liu, J. and Wei, W. Engineering nanobodies for next-generation molecular imaging. Drug Discov. Today 2022. 27: 1622-1638.
Awad, R. M., Meeus, F., Ceuppens, H., Ertveldt, T., Hanssens, H., Lecocq, Q., Mateusiak, L. et al., Emerging applications of nanobodies in cancer therapy. Int. Rev. Cell Mol. Biol. 2022. 369: 143-199.
Tunggal, J. K., Cowan, D. S. M., Shaikh, H. and Tannock, I. F., Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 1999. 5: 1583-1586.
Jain, R. K., Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990. 9: 253-266.
Matsumura, Y. and Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agents Smancs. Cancer Res. 1986. 46: 6387-6392.
Chauhan, V. P., Stylianopoulos, T., Boucher, Y. and Jain, R. K., Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2011. 2: 281-298.
Thurber, G. M., Schmidt, M. M. and Wittrup, K. D., Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 2008. 29: 57-61.
van Osdol, W., Fujimori, K. and Weinstein, J. N., An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier”. Cancer Res. 1991. 51: 4776-4784.
Saga, T., Neumann, R. D., Heya, T., Sato, J., Kinuya, S., Le, N., Paik, C. H. et al., Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc. Natl. Acad. Sci. USA 1995. 92: 8999-9003.
Sato, J., van Osdol, W., Weinstein, J. N. and Perez-Bacete, M. J., Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992. 52: 5144-5153.
Lee, C. M. and Tannock, I. F., The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010. 10: 255.
Baker, J. H. E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J. T. and Minchinton, A. I., Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin. Cancer Res. 2008. 14: 2171-2179.
Rhoden, J. J. and Wittrup, K. D., Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J. Pharm. Sci. 2012. 101: 860-867.
Debie, P., Lafont, C., Defrise, M., Hansen, I., van Willigen, D. M., van Leeuwen, F. W. B., Gijsbers, R. et al., Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumors. J. Control Release 2020. 317: 34-42.
Wittrup, K. D., Thurber, G. M., Schmidt, M. M. and Rhoden, J. J., Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012. 503: 255-268.
Erreni, M., D'Autilia, F., Avigni, R., Bolli, E., Arnouk, S. M., Movahedi, K., Debie, P., et al., Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting. Theranostics 2023. 13: 355-373.
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., et al., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010. 70: 5728-5739.
Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., Movahedi, K. et al., Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 2014. 74: 24-30.
Van Overmeire, E., Stijlemans, B., Heymann, F., Keirsse, J., Morias, Y., Elkrim, Y., Brys, L. et al., M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 2016. 76: 35-42.
Wang, X., Sathe, A. A., Smith, G. R., Ruf-Zamojski, F., Nair, V., Lavine, K. J., Xing, C. et al., Heterogeneous origins and functions of mouse skeletal muscle-resident macrophages. Proc. Natl. Acad. Sci. USA 2020. 117: 20729-20740.
Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., Bouwens, L. et al., Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012. 72: 4165-4177.
Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S. et al., Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013. 24: 695-709.
De Vlaeminck, Y., Bonelli, S., Awad, R. M., Dewilde, M., Rizzolio, S., Lecocq, Q., Bolli, E. et al., Targeting neuropilin-1 with nanobodies reduces colorectal carcinoma development. Cancers (Basel) 2020. 12: 3582.
Bolli, E., Scherger, M., Arnouk, S. M., Pombo Antunes, A. R., Straßburger, D., Urschbach, M., Stickdorn, J. et al., Targeted repolarization of tumor-associated macrophages via imidazoquinoline-linked nanobodies. Adv. Sci. (Weinh) 2021. 8: 2004574.
Bolli, E., D'Huyvetter, M., Murgaski, A., Berus, D., Stangé, G., Clappaert, E. J., Arnouk, S. et al., Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors. J. Control Release 2019. 314: 1-11.
Tripathi, C., Tewari, B. N., Kanchan, R. K., Baghel, K. S., Nautiyal, N., Shrivastava, R., Kaur, H. et al., Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 2014. 5: 5350-5368.
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H. et al., HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008. 13: 206-220.
Leek, R. D., Hunt, N. C., Landers, R. J., Lewis, C. E., Royds, J. A. and Harris, A. L., Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 2000. 190: 430-436.
Grimshaw, M. J., Wilson, J. L. and Balkwill, F. R., Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur. J. Immunol. 2002. 32: 2393-2400.
Matschurat, S., Knies, U. E., Person, V., Fink, L., Stoelcker, B., Ebenebe, C., Behrensdorf, H. A. et al., Regulation of EMAP II by hypoxia. Am. J. Pathol. 2003. 162: 93-103.
Lewis, J. S., Landers, R. J., Underwood, J. C., Harris, A. L. and Lewis, C. E., Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 2000. 192: 150-158.
Kuwabara, K., Ogawa, S., Matsumoto, M., Koga, S., Clauss, M., Pinsky, D. J., Lyn, P. et al., Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. USA 1995. 92: 4606-4610.
Harmey, J. H., Dimitriadis, E., Kay, E., Redmond, H. P. and Bouchier-Hayes, D., Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1. Ann. Surg. Oncol. 1998. 5: 271-278.
Lwin, T. M., Turner, M. A., Amirfakhri, S., Nishino, H., Debie, P., Cosman, B. C., Hoffman, R. M. et al., Rapid tumor-labeling kinetics with a site-specific near-infra red anti-CEA nanobody in a patient-derived orthotopic xenograft mouse model of colon cancer. J. Surg. Oncol. 2021. 124: 1121-1127
Roopenian, D. C. and Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007. 7: 715-725.
Kontermann, R. E., Half-life extended biotherapeutics. Expert Opin. Biol. Ther. 2016. 16: 903-915.
Dennis, M. S., Zhang, M., Gloria Meng, Y., Kadkhodayan, M., Kirchhofer, D., Combs, D. and Damico, L. A., Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 2002. 277: 35035-35043.
Cantante, C., Lourenço, S., Morais, M., Leandro, J., Gano, L., Silva, N., Leandro, P. et al., Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. J. Biotechnol. 2017. 253: 23-33.
Hopp, J., Hornig, N., Zettlitz, K. A., Schwarz, A., Fuß, N., Müller, D. and Kontermann, R. E., The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng. Des. Sel. 2010. 23: 827-834.
Stork, R., Campigna, E., Robert, B., Müller, D. and Kontermann, R. E., Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J. Biol. Chem. 2009. 284: 25612-25619.
Xenaki, K. T., Dorrestijn, B., Muns, J. A., Adamzek, K., Doulkeridou, S., Houthoff, H., Oliveira, S. et al., Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics 2021. 11: 5525-5538.
Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E. et al., The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res. Ther. 2015. 17: 135.
Sparkes, A., De Baetselier, P., Brys, L., Cabrito, I., Sterckx, Y. G., Schoonooghe, S., Muyldermans, S. et al., Novel half-life extended anti-MIF nanobodies protect endotoxic shock. FASEB J. 2018. 32: 3411-3422.
Li, L., Zhu, Y., Liu, M., Jin, D., Zhang, L., Cheng, J. and Liu, Y., Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation. J. Inorg. Biochem. 2021. 223: 111553.
Banks, W. A., From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat. Rev. Drug Discov. 2016. 15: 275-292.
Obermeier, B., Daneman, R. and Ransoho, R. M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013, 19: 1584-1596.
Stemmler, J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N. and Heinemann, V., Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J. Clin. Oncol. 2006. 24: 1525.
Zheng, F., Pang, Y., Li, L., Pang, Y., Zhang, J., Wang, X. and Raes, G., Applications of nanobodies in brain diseases. Front. Immunol. 2022. 13: 978513.
Perruchini, C., Pecorari, F., Bourgeois, J.-P., Duyckaerts, C., Rougeon, F. and Lafaye, P., Llama VHH antibody fragments against GFAP: better diffusion in fixed tissues than classical monoclonal antibodies. Acta Neuropathol. 2009, 118: 685-695.
Li, T., Vandesquille, M., Koukouli, F., Dudeffant, C., Youssef, I., Lenormand, P., Ganneau, C., et al., Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J. Control Release 2016, 243: 1-10.
Puttemans, J., Dekempeneer, Y., Eersels, J. L., Hanssens, H., Debie, P., Keyaerts, M., Windhorst, A. D. et al., Preclinical targeted α- and β−-radionuclide therapy in HER2-positive brain metastasis using camelid single-domain antibodies. Cancers (Basel) 2020. 12: 1017.
De Vlaminck, K., Romão, E., Puttemans, J., Pombo Antunes, A. R., Kancheva, D., Scheyltjens, I. et al., Imaging of glioblastoma tumor-associated myeloid cells using nanobodies targeting Signal Regulatory Protein Alpha. Front. Immunol. 2021. 12: 777524.
Li, T., Bourgeois, J. P., Celli, S., Glacial, F., Le Sourd, A. M., Mecheri, S., Weksler, B. et al., Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: applications to brain imaging. FASEB J. 2012. 26: 3969-3979.
Pombo Antunes, A. R., Scheyltjens, I., Lodi, F., Messiaen, J., Antoranz, A., Duerinck, J., Kancheva, D. et al., Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 2021. 24: 595-610.
Ruiz-Lopez, E., Jovcevska, I., Gonzalez-Gomez, R., Tejero, H., Al-Shahrour, F., Muyldermans, S. and Schuhmacher, A. J.. Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma. Sci. Rep. 2022. 12: 22581.
Iqbal, U., Albaghdadi, H., Luo, Y., Arbabi, M., Desvaux, C., Veres, T., Stanimirovic, D. et al., Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br. J. Cancer 2010. 103: 1606-1616.
Porčnik, A., Novak, M., Breznik, B., Majc, B., Hrastar, B., Šamec, N., Zottel, A. et al., Trim28 selective nanobody reduces glioblastoma stem cell invasion. Molecules 2021:26: 5141.
De Groof, T. W. M., Mashayekhi, V., Fan, T. S., Bergkamp, N. D., Sastre Toraño, J., van Senten, J. R., Heukers, R. et al., Nanobody-targeted photodynamic therapy selectively kills viral GPCR-expressing glioblastoma cells. Mol. Pharm. 2019. 16: 3145-3156.
Heukers, R., Fan, T. S., de Wit, R. H., van Senten, J. R., De Groof, T. W. M., Bebelman, M. P., Lagerweij, T. et al., The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth. Oncogene 2018. 37: 4110-4121.